Clinical Trials DEA Marijuana Programs 
Americans for Safe Access
JUNE 2, 2020
On March 23, DEA published a proposed rulemaking —“Controls to Enhance the Cultivation of Marihuana for Research in the United States”—in the Federal Register (85 FR 16292), involving who can grow cannabis in bulk for research purposes.
Cannabis Law Report
MARCH 30, 2022
The action represents one of the very few occasions that members of the Senate have ever advanced a marijuana-related reform bill. Under this proposal, the AG is also provided with the ability to authorize increases in the total number of federally approved marijuana cultivators. BILLS-117s253es. The full text of S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Canna Law Blog
NOVEMBER 27, 2021
DMT, like its sister psychedelics (LSD, MDMA, psilocybin … and even marijuana), is a Schedule I controlled substance. So according to the DEA, its abuse potential is high and it has no medical use. In fact, Small Pharma has been conducting trials as reported by the BBC and expanded its clinical trial this past summer.
SpeedWeed
AUGUST 11, 2021
The grant comes from Michigan’s 2021 Veteran Marijuana Research Grant Program , and is funded by the state’s recreational cannabis taxes. With a goal of determining the “the efficacy of marijuana in treating the medical conditions of United States armed services veterans and preventing veteran suicide.”. MAPS Makes History.
Cannabis Law Report
MAY 29, 2022
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. Clinical Trials and Human Subject Protections. Before the drug approval process even begins, sponsors must initiate clinical investigations by first filing an Investigational New Drug Application (IND) with FDA.
Cannabis Law Report
APRIL 21, 2022
The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment.
MedicalJane
JUNE 29, 2018
The FDA announced in a press release on Monday that it had approved the “first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.”. Use of CBD in seizure prevention is well-documented with research ; and now, after conducting its own trials, the FDA appears to agree.
Expert insights. Personalized for you.
230 
Let's personalize your content